Nevertheless, the in vitro and in vivo evidence supporting the use of ERBBi in melanoma is strong, and further investigation into their use in melanoma patients with high levels of EGFR expression is warranted, particularly given the evidence for its role in driving anoikis resistance. The gene discussed is EGFR; the disease is melanoma.